Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study

Abstract

For a wide spectrum of underlying conditions, we observed no increase in liver injury by micafungin and possibly a reduced risk of renal dysfunction in comparison with other PAF medications.